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Abstract
We performed whole genome sequencing of a cidofovir {[(S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl) cytosine] 
[HPMPC]}-resistant (CDV-R) strain of Monkeypoxvirus (MPV). Whole-genome comparison with the wild-type (WT) 
strain revealed 55 single-nucleotide polymorphisms (SNPs) and one tandem-repeat contraction. Over one-third of all 
identified SNPs were located within genes comprising the poxvirus replication complex, including the DNA 
polymerase, RNA polymerase, mRNA capping methyltransferase, DNA processivity factor, and poly-A polymerase. Four 
polymorphic sites were found within the DNA polymerase gene. DNA polymerase mutations observed at positions 314 
and 684 in MPV were consistent with CDV-R loci previously identified in Vaccinia virus (VACV). These data suggest the 
mechanism of CDV resistance may be highly conserved across Orthopoxvirus (OPV) species. SNPs were also identified 
within virulence genes such as the A-type inclusion protein, serine protease inhibitor-like protein SPI-3, Schlafen ATPase 
and thymidylate kinase, among others. Aberrant chain extension induced by CDV may lead to diverse alterations in 
gene expression and viral replication that may result in both adaptive and attenuating mutations. Defining the 
potential contribution of substitutions in the replication complex and RNA processing machinery reported here may 
yield further insight into CDV resistance and may augment current therapeutic development strategies.
Background
Poxviruses are large, enveloped, pleomorphic dsDNA
viruses that infect a diverse array of mammals, reptiles,
and insects [1]. The causative agent of Smallpox, Variola
virus (VARV) is a member of the OPV genus. Smallpox
was declared eradicated in 1980, however, natural or
illicit re-emergence poses a risk for a growing non-vacci-
nated population [2]. MPV is a re-emerging pathogen
within the OPV genus that causes sporadic outbreaks in
monkeys and humans in West and Central Africa and,
recently, in North America [3]. MPV can cause human
disease clinically similar to Smallpox but with lower mor-
bidity and mortality rates [4]. Although terrestrial and
arboreal rodents and mammals are thought to play a role
in MPV transmission, human to human transmission is
known to occur [5].
Poxviruses possess large, complex genomes that encode
their own viral replication machinery in addition to a
plethora of immunomodulating proteins [1]. The major
components of the poxviral replication complex include
the poxvirus DNA polymerase (DNApol, E9L), transcrip-
tion factor heterodimer (vETF), DNA-dependent RNA
polymerase, RNA polymerase accessory protein (RAP94),
viral poly-A polymerase (VP55/VP39), capping methyl-
transferase (D1/D10), and the DNA polymerase proces-
sivity factor (A20) [1,6]. Chemotherapeutic strategies for
poxvirus infection have largely targeted viral DNA syn-
thesis in order to disrupt the virus replication cycle [7,8].
A number of nucleoside/nucleotide analogs are avail-
able that inhibit OPVs [7]. The acyclic nucleoside phos-
phonate analogue (S)-1-[3-hydroxy-2-phosphonyl-
methoxypropyl)] cytosine ((S)-HPMPC) or cidofovir
(CDV) has been shown to inhibit in vitro viral replication
of most known DNA viruses including poxviruses [9-11].
Recent studies suggest a mechanism whereby CDV may
allosterically reposition the 3' nucleophile of terminal and
short +strand synthesis products leading to aberrant
chain extension [12,13]. Using the VACV DNApol E9L,
previous studies indicate CDV incorporation slows chain
elongation and inhibits DNA synthesis [12]. In addition,
CDV has been shown to inhibit 3' to 5' exonuclease activ-
ity of E9L when incorporated in the penultimate position
relative to the primer terminus [12]. By altering chain
extension CDV affects DNA synthesis, a key regulator of
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poxvirus gene expression. Thus, alterations in gene
expression and replication are likely to occur during CDV
exposure, and, could result in mutations affecting con-
served determinants of the virus life cycle.
Cidofovir activity appears to be conserved in dsDNA
viruses providing a common strategy for inhibiting viral
replication in important human diseases caused by these
virus families [14,8,15]. Substitutions in the DNApol exo-
nuclease (A314T) and polymerase (A684V) domains of
the VACV DNA polymerase have previously been
mapped and shown to confer CDV resistance [16,17].
CDV resistant strains in other members of the OPV
genus, including MPV, Camelpoxvirus (CMPV), and
Cowpoxvirus (CWPV) have already been reported [15].
DNApol mutations conferring resistance to CDV may be
conserved among non-VACV OPV species although,
presently, such sequence analyses have not been per-
formed. Indeed, a portion of resistance attributes are
likely to be conserved across dsDNA viruses. A number
of additional features of CDV-resistance remain unchar-
acterized. CDV resistant strains frequently display an
attenuated phenotype [18,15] through yet uncharacter-
ized natural genetic alterations. In addition, it has been
suggested that, in some cases, resistance to CDV requires
mutations outside the DNA polymerase. One previous
study identified a CDV-R VACV which exhibited a single
non-essential substitution in the DNApol that upon
reconstruction did not confer CDV resistance [18]. To
date, such loci elsewhere in the genome remain
unknown. Whole-genome sequence data could provide
valuable insight into breadth of mutations induced by
CDV exposure and yield insight into further requisites for
attenuation and resistance.
We report here the first whole genome sequence of a
CDV-R poxvirus. Our data revealed a plethora of substi-
tutions within the CDV-R MPV genome, one-third of
which were distributed throughout the viral replication
machinery. Substitutions identified in the MPV DNA
polymerase are consistent with those previously observed
in VACV suggesting CDV-resistance determinants may
be conserved in the OPV genus. The numerous substitu-
tions observed throughout the replication and RNA pro-
cessing machinery suggest multiple accrued mutations
may alter the timing and regulation of the virus life cycle
under CDV exposure. Novel loci reported here may
inform future studies aimed at mechanistic interaction of
CDV with the replication complex.
Results and Discussion
Whole genome comparison of CDV-R and WT strains of
Monkeypox revealed 55 single nucleotide polymor-
phisms (SNPs) including four insertions, six deletions,
and 44 nucleic acid substitutions (Table 1, Figure 1, 2). A
total of 10 intergenic and 45 intragenic SNPs, were
observed that include 17 synonomous, 26 nonsynono-
mous substitutions and one tandem repeat contraction
(Table 1). Over a third of all observed SNPs occurred
within genes involved in virus replication and DNA
metabolism. The physical distribution of all observed
SNPs and indels (insertions/deletions) are illustrated in
Figure 1.
DNA replication
Poxviruses exert exquisite control over the timing of gene
expression to regulate genome replication and virion
assembly [19]. Five early proteins are essential for poxvi-
rus DNA replication, including the DNA polymerase
(E9), DNA-independent nucleoside triphosphatase
(NTPase, D5), uracil DNA glycosylase (D4), protein
kinase B1, and DNA processivity factor (VPF/A20) [19,6].
In our study, substitutions were observed in the 3' to 5'
exonuclease and 5' to 3' polymerase domains of the MPV
DNA polymerase (Table 1, Figure 2, Figure 3A, B) consis-
tent with previous studies in VACV [10,12,20]. A total of
four non-synonomous substitutions and 1 synonymous
substitution were observed in the MPV DNA polymerase
gene (ORF 062) (Table 1). The CDV-R MPV DNApol
encoded substitutions A314V and A684T at conserved
positions respective to CDV-R VACV [16], although the
substituted residues appear reversed (MPV = V314/T684,
VACV = T314/V684). In both cases, A314 and A684 in
MPV and VACV are replaced by slightly larger residues
with differing polar characters (threonine = +4.9, valine =
-2.0). Two novel substitutions A613T and T808M in the
MPV CDV-R strain were located within and flanking the
polymerase domain, respectively (Figure 2).
We utilized predictive modeling software to extrapolate
potential structural changes mediated by these substitu-
tions in the MPV DNA polymerase protein. Predicted
topological features of the CDV-R DNA polymerase
A314V substitution in the exonuclease domain appears to
increase the regional hydrophobicity, alter surface con-
tour and decrease surface exposure (Figure 4A, B, Figure
5A, B, C, Table 2) at this locus. The A684T substitution in
the polymerase domain appears to exhibit a decrease in
the regional hydrophobicity (Figure 5D) and an increase
in surface contour and exposure (Figure 5E, F), including
a predicted shift from alpha helical to beta sheet topology
(Figure 6A, B). Similar analysis suggests a slight increase
in surface exposure at the A613T locus and a moderate
loss of surface exposure at the T808M locus (Table 2). It
has been hypothesized that the resistant mutation at the
A314 locus in the exonuclease domain may facilitate exci-
sion of CDV during replication, while mutation at A684,
located adjacent to the DNA-binding pocket (Figure 3A,
B), may be involved in nucleotide selection and discrimi-
nation of CDV [20]. Solving the 3-D structure of a poxvi-Farlow et al. Virology Journal 2010, 7:110
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Figure 1 Physical location of MPV CDV-R substitutions and indels in the MPV Zaire 1979-005 genome. Gene spacing is based on NCBI graphics 
output http://www.ncbi.nlm.nih.gov/nuccore/68449077?report=graph&log$=seqview. Open reading frames (ORFs) corresponding to sites listed in 
Table 1 are noted above horizontal axis.
Figure 2 Viral replication-associated amino acid substitutions from Table 1.Farlow et al. Virology Journal 2010, 7:110
http://www.virologyj.com/content/7/1/110
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Table 1: Genome-wide SNP/indel attributes of CDV-R MPV.
Locationa Mutation Amino Acid Z79-ORFb COP-ORFc Gene GenBank#
6166 T insertion NA IGd NA NA NA
6863 G to A P9S 9 unknown ankyrin-like AAY97204
11360 T insertion NA 15 unknown ankyrin/host Range AAY97210
13685 C to T A589T 17 C9L ankyrin AAY97212
19143 C to T NA IGd NA NA NA
27141 C deletion A168Q 32 K2L serine protease inhibitor-like protein 
SPI-3
AAY97227
32192 T deletion H385L 38 F3L Kelch-like AAY97233
33518 C to T silent 39 I4L/F4L ribonucleoside-diphosphate reductase AAY97234
35560 T deletion NA IGd NA NA NA
35593 G to A T68M 42 F7L unknown AAY97237
40212 C to A silent 47 F12L IEV associated AAY97242
44808 C to T R342H 53 E1L poly-A polymerase catalytic subunit 
VP55
AAY97248
48134 A to T NA IGd NA NA NA
50728 T to A silent 59 E6R unknown AAY97254
53128 T to C silent 61 E8R assoc.s with IV/IMV and cores; F10L 
kinase substrate
AAY97256
53738 G to A V256I 61 E8R assoc.s with IV/IMV and cores; F10L 
kinase substrate
AAY97256
54066 T to C silent 62 E9L DNA polymerase AAY97257
54400 G to A T808M 62 E9L DNA polymerase AAY97257
54773 C to T A684T 62 E9L DNA polymerase AAY97257
54986 C to T A613T 62 E9L DNA polymerase AAY97257
55882 G to A A314V 62 E9L DNA polymerase AAY97257
58655 T to C silent 65 01L unknown AAY97260
64425 A insertion NA IGd NA NA NA
73563 A deletion NA IGd NA NA NA
77811 G to A M207I 85 L1R myristylprotein AAY97280
82937 C to T silent 93 J4R DNA-dependent RNA polymerase 
subunit rpo22
AAY97288
84110 G to A silent 95 J6R DNA-dependent RNA polymerase 
subunit rpo147
AAY97290
84578 A to C K355N 95 J6R DNA-dependent RNA polymerase 
subunit rpo147
AAY97290
85471 T to G L653R 95 J6R DNA-dependent RNA polymerase 
subunit rpo147
AAY97290
89604 G to A silent 99 H4L RNA polymerase-assoc. transcription 
factor RAP94
AAY97294
89691 C to T M715I 99 H4L RNA polymerase-assoc. transcription 
factor RAP94
AAY97294
99891 T to C silent 107 D5R NTPase, DNA replication AAY97302
103281 C to T A289T 110 D8L carbonic anhydrase/Virion AAY97305
104948 C to A L42I 111 D9R nudix-hydrolase/RNA decapping AAY97307
107809 C to T H122Y 114 D12L small capping enzyme, 
methyltransferase
AAY97309Farlow et al. Virology Journal 2010, 7:110
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108002 G to A S186N 114 D12L small capping enzyme, 
methyltransferase
AAY97309
119244 G to A silent 125 A9L membrane protein AAY97320
129030 C to T S216L 138 A20R DNA processivity factor AAY97333
129340 G to A silent 138 A20R DNA processivity factor AAY97333
137047 A to G L324S 145 A25L A type inclusion protein (CPXV) AAY97340
138486 ATCATC 
deletion
DD-dele 146 A26L P4c: CWPVA27L, A-type inclusion 
protein
AAY97341
149213 G to A silent 161 A42R profilin homolog AAY97356
150527 C to T A284T 164 A44L bifunctional hydroxysteroid 
dehydrogenase
AAY97356
151960 T to C silent 166 A46R IL-1 signaling inhibitor AAY97361
154086 G deletion frameshift 169 A48R thymidylate kinase AAY97364
162118 C to T H268Y 178 B2R/B3R Schlafen ATPase AAY97370
163857 C to T A271V 179 B4R ankyrin AAY97371
166078 A to T Q9H 181 B6R ankyrin AAY97373
168859 T to A NA IGd NA NA NA
175168 C to T silent 192 B18R IFN-α/β-receptor orthologue AAY97385
176348 T to C silent 193 unknown ankyrin AAY97386
177838 T insertion NA IGd NA NA NA
183499 T to C silent 197 CWP_B22R surface glycoprotein AAY97391
189631 T to C NA IGd NA NA NA
190055 A deletion NA IGd NA NA NA
a indicates position of mutation relative to the MPV Zaire 1979-005 genome sequence (DQ011155.1). b indicates open reading frame (ORF) 
designations within the Zaire-1979-005 genome. c specifies open reading frame designations within the VACV Copenhagen genome (M35027.1). 
d designates an intergenic non-coding locus. e designates deletion of two aspartic acid residues (D) from the c-terminal poly D repeat of gene 164 
(homologue of VACV A26l).
Table 1: Genome-wide SNP/indel attributes of CDV-R MPV. (Continued)
rus DNApol may provide further clarity on the positional
activity and functional attributes of these mutations.
DNA processivity factor
Fully processive DNA polymerase activity is mediated by
the heterodimeric A20/D4 DNA processivity factor [21].
A20 is essential for genome replication and may form a
multi-enzyme replication complex with D4, D5, and H5
that is postulated to stabilize the DNA replication com-
plex [22]. D5R is a nucleic acid independent nucleoside
triphosphatase (NTPase) that is crucial for infection
[23,24] and may play a role in priming DNA synthesis at
the replication fork [25]. In our study, CDV-R MPV
exhibited a substitution in A20 (S216L) that lies directly
within the D5 NTPase/primase binding domain (Table 1,
Figure 2) [22,26].
Thymidylate kinase
The poxvirus thymidylate kinase (TMPK) encodes a 48
kDa serine threonine protein kinase (A48R) [27] that reg-
ulates deoxyribonucleotide triphosphate pools in con-
junction with the viral thymidine kinase. Similar to
cellular TMPK, A48R functions as a homodimer where
dimerization is mediated by proper orientation of the α2,
α3, α6 helices [28]. The quaternary structure of A48R is
distinct in orientation from that of the host conferring
broader substrate specificity [28]. We observed a SNP
deletion at residue 600 in the CDV-R MPV gene that
results in a frameshift mutation at amino acid Q201 and
replacement of the c-terminus residues "QLWM" with
residues "NCGC" (Table 1, Figure 7 and inset). The
frameshift results in a more pronounced turn region con-
ferred by the proximal P198 predicted by chou-Fasman
and Gernier-Robson algorithms (data not shown). This
alteration may affect the dimerization interface of the
homodimer given that the c-terminal residues support
the α6 helix which mediates dimerization (Figure 7)[28].
It is interesting to speculate whether such a change in
secondary structure could affect protein function during
CDV exposure, such as discriminatory selection between
CDV diphosphate and cellular dCTP pools.Farlow et al. Virology Journal 2010, 7:110
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Page 6 of 15
Figure 3 MPV CDV-R mutations mapped onto the 3D structures of herpes simplex 1 DNA polymerase. Mutations A314V (red), A684T (yellow), 
and T808M (blue) are illustrated in view of the entire protein (A) and DNA binding cleft (B).
Figure 4 Topological feature maps of CDV-R (A) and WT (B) MPV DNA pol 3'-5' exonuclease domain. Plotted residues 1-190 correspond to 162-
351 in the MPV DNA pol exonuclease domain. The A314V substitution (Table 1) corresponds to position 153 in the plot. For comparison, regions of 
difference in secondary structure and biochemical characteristics between CDV-R and WT are designated by shaded areas in the vertical orange box.Farlow et al. Virology Journal 2010, 7:110
http://www.virologyj.com/content/7/1/110
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RNA polymerase machinery
The primary components of the poxviral RNA machinery
consist of the poxvirus DNA-dependent RNA polymerase
(rpo147), the viral early transcription factor vETF (D1/
D12) heterodimer, eight RNA polymerase subunits,
RAP94, VP55/VP39 subunits of the viral poly (A) poly-
merase, the capping methyltransferase (D1/D12), and the
D9 subunit of the mRNA decapping enzyme (Table 1,
Figure 2) [1]. Proteins RAP94, NPHI (D11), and D1/D12
constitute early termination factors [19]. Poxvirus RNA
pol contains eight common subunits including rpo147,
rpo132, rpo35, rpo30, rpo22, rpo19, rpo18, rpo7 [1]. The
dual functional ninth subunit, RAP94, is absent in inter-
mediate and late replication complexes [29] and is
thought to function as an early transcription factor dock-
ing platform [30,31]. Vaccinia Early Transcription Factor
(VETF), comprising D6R and A7L, binds to early promot-
ers, recruits RAP94-containing RNA pol, and nucleates a
stable pre-initiation complex at the early promoter [31].
Viral mRNA capping and addition of poly(A) tails are
generated by the heterodomeric proteins D1/D12 and
VP55/VP39, respectively [32-34]. In addition, cellular
RNA pol II and TATA-binding proteins (TBPs) are
recruited to poxvirus replication complexes, possibly to
early and late viral promoters that show similarity to cel-
lular RNA pol II TATA-box promoters [35,36]. Roles for
such host proteins in the viral life cycle remain unknown.
Several poxviral RNA polymerase subunits share limited
sequence similarity with cellular RNA pol II subunits
[36]. Previous studies indicate the largest subunit of the
poxvirus RNApol (rpo147) exhibits the greatest homol-
ogy to cellular RNApol II [37,38] while vaccinia VETF
(D1-D12) and RAP94 show sequence similarity to cellular
TBP-TFIID and RAP30-TFIIF, respectively [39]. In this
study, we observed amino acid substitutions in MPV
RNA pol II subunits including rpo147 (K355N, L653R),
Figure 5 Biochemical and surface prediction plots of MPV CDV-R and WT DNA pol substitutions. Features of the A314V locus are presented in 
plots A-C, and A684T in plots D-F.Farlow et al. Virology Journal 2010, 7:110
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RAP94 (M715I), VP55 (R342H), D12 (H122Y, S186N),
and D9 (L42I) (Table 1, Figure 2).
RNA polymerase rpo147
The L653R substitution in the poxvirus rpo147 subunit
lies directly in a homologous region of domain 4 in the
yeast RNA polymerase II (RNA pol II) Rpb1 subunit
(yeast E734R) that comprises the funnel (secondary chan-
nel) domain (Figure 8A, B, C) [40]. The domain lies at the
juncture of the catalytic domain and the outside medium
and is thought to mediate NTP entry and selection and
support exonuclease proofreading [40]. The funnel
domain may mediate binding RNA cleavage stimulatory
factor TFIIS (Figure 9B) [41], which stimulates RNA pol
Figure 6 Topological feature maps of CDV-R (A) and WT (B) MPV DNA pol domain. type B DNA polymerase residues 525-806, T808M = T284,. 
Plotted residues 1-330 correspond to residues 525-806 in the MPV DNA pol catalytic domain. The A613T, A684T, and T808M substitutions (Table 1) 
correspond to positions 89, 160, and 284 in the plot. For comparison, regions of difference in secondary structure and biochemical characteristics be-
tween CDV-R and WT are designated by shaded areas in the vertical orange box.Farlow et al. Virology Journal 2010, 7:110
http://www.virologyj.com/content/7/1/110
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II nuclease activity following transcriptional arrest [42]
and recruits RNA pol II and TFIIB to the promoter [43].
In addition, this domain is also the binding site for anti-
microbial RNA pol inhibitors including α-amanitin and
targetoxin [44-46]. The MPV CDV-R L653R substitution
lies adjacent to residues previously shown to mediate cel-
lular RNA pol II inhibitor α-amanitin resistance (Figure
8B and 8C) [45]. Protein structure prediction indicates
the L653R mutation may decrease regional hydrophobic-
ity, and increases motif surface exposure (Table 2). The
extent of homology of poxviral rpo147 and rpo30 with
cellular RNA pol II Rpb 1 and TFIIS [38,47] suggest gen-
eral features of their interaction may be conserved.
The MPV CDV-R K355N substitution (yeast G422) lies
directly within the docking domain near the RNA exit
groove of RNA pol II (Figure 8A and 9A)[48]. The RNA
pol II docking domain binds TFIIB through contact resi-
dues 407-RDSGDRIDLRYSK-419 located within a larger
conserved 67 amino acid motif [48]. The MPV CDV-R
K355N mutation lies within the docking domain (in pur-
ple) immediately adjacent to the contact residue motif
(Figure 9A). A significant change in predicted secondary
structure is imparted by the K355N substitution includ-
ing a pronounced increase in the surface contour (Table
2). The effect of CDV on the viral and cellular RNA poly-
merase machinery has not been evaluated. It is possible
that viral RNA pol may be subject to either direct or indi-
rect effects of CDV via dCTP selection in the presence of
CDV or transcriptional arrest due to disrupted mRNA
transcripts. In any case, alteration of the functional activ-
ity of either the funnel or docking domain could signifi-
cantly alter pre-initiation complex formation and affect
transcriptional regulation and promoter recruitment.
Capping methyltransferase
The poxvirus mRNA capping machinery, encoded by the
D1R and D12L genes in VACV, catalyzes viral mRNA
capping and regulates gene transcription [49,50]. The D1/
D12 heterodimer mediates 5' methylation of viral tran-
scripts [32], promotes early gene transcription termina-
tion [51], and regulates initiation of intermediate gene
expression [52]. Methyltransferase (MT) catalysis is
mediated by the C-terminal active domain of D1R.
Triphosphatase and quanylyltransferase activity are
located within the N-terminal domain [53]. Following
heterodimerization, the stimulatory D12 subunit confers
full D1R MT activity by stimulating MT catalysis up to 50
fold [54,55].
We observed two substitutions (H122Y and S186N) in
the MPV CDV-R strain D12 orthologue (ORF114) (Table
1, Figure 2). Both substitutions lie within structural
motifs that mediate allosteric interactions important for
D1-D12 heterodimerization and MT activity (Figure 10A
and 10B, in red and yellow) [53,56]. The basic H122 resi-
due flanks two neutral residues, 120N and 121N, that
affect important polar interactions between D1 and D12
Table 2: Biochemical and topological attributes of CDV-R MPV mutations
Protein ORFa Amino Acid Domain  Polarityb  
Hydropathyb
Surface 
Exposured
Surface 
Contoure
DNA pol E9L A314V exonuclease 0.1 2.4 decrease increase
DNA pol E9L A613T polymerase 6.8 2.5 increase increase
DNA pol E9L A684T polymerase 6.8 2.5 increase increase
DNA pol E9L T808M NA 6.4 2.6 decrease decrease
RNA pol 
subunit rpo147
J6R K355N TFIIB docking 5.3 3.12 decrease increase
RNA pol 
subunit rpo147
J6R L653R funnel 22.3 8.3 increase increase
mRNA capping 
enzyme small 
subunit
D12L H122Y dimerization 4.2 1.9 increase decrease
mRNA capping 
enzyme small 
subunit
D12L S186N dimerization 4.6 2.7 increase decrease
poly-A pol 
catalytic 
subunit VP55
E1L R342H dimerization 9.7 0.7 decrease decrease
a specifies ORFs relative to Copenhagen strain. b changes in polarity and hydropathy due to amino acid substitutions were calculated using Kyle 
and Doolittle algorithm in Lazergene (DNAstar) software. d surface exposure and e contour were determined using the Emini method and 
Jameson-Wolf algorithm, respectively (DNAstar software).Farlow et al. Virology Journal 2010, 7:110
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(Figure 10A and 10B, in blue)[53,56]. CDV-R residue
Y122 lies directly within an 11-aa motif (119-130) in the
central domain region that plays a direct role in heterodi-
merization (yellow residues shown in Figure 10A and
10B) [53]. In addition, this short motif forms inter-sub-
unit contacts with the D1R N-terminal α-Z helix and is
proposed to allosterically stabilize substrate binding by
D1R [53]. Predicted changes in secondary structure due
to the H122Y substitution indicate a beta strand reduc-
tion (data not shown) and decreased surface contour and
exposure (Table 2). Residue S186 lies with the conserved
motif 183-KCVSDSWLKDS (red residues Figure 6F) that
was previously noted as a highly structured motif which
integrates several local and distal interactions which may
play a major role in proper tertiary folding [53]. This
position also flanks motif 189-WLKDS that may consti-
tute a portion of the D1 subunit docking site [53]. S186 is
in closest proximity to D1 residues S589 (teal) and T84
(magenta) (Figure 10A) and lies near the D1-D12 inter-
face (Figure 10B).
D12 structurally stabilizes D1 through allosteric inter-
actions that mediate heterodimerization and substrate
affinity [57]. Predicted changes in secondary structure
observed here could affect the D12/D1 interface, and
thereby possibly alter viral gene expression. Affecting D1/
D12 heterodimerization has previously been proposed as
a potential therapeutic target for rational drug design
[58]. We also observed an L42I substitution in the D9
subunit of the mRNA decapping enzyme (T able 1) that
acts primarily on early transcripts [59]. The L42 residue
appears highly conserved throughout the Chordopoxviri-
nae [59]. The D9/D10 heterodimeric decapping enzyme
has been shown to decrease the levels of viral and cellular
capped mRNAs and their translated products perhaps to
delineate more responsive transitions between early and
late stage gene expression [59].
VP55 poly(A) polymerase
Similar to eukaryotic mRNA transcripts, viral mRNAs
possess a m7G(5')pppGm cap structure and a 3' poly(A)
tail. This posttranscriptional modification is carried out
by the viral capping heterodimer VP39 and the heterodi-
meric poly(A) polymerase (PAP) protein that catalyzes 3'
adenylate extension [33,34]. The large subunit of PAP is
the catalytically active VP55 poly(A) polymerase and
requires the small subunit (VP39) for full processivity
[60]. VP39 performs dual functions and exhibits methyl-
transferase activity distinct from its role as a processivity
factor for VP55 polyadenylation. VP55 acquires proces-
sivity by binding VP39 at a dimerization surface region
distal to the VP39 methyltransferase cleft [61]. Confor-
mational changes from this interaction occur in the VP39
methyltransferase, and VP55-VP39 interaction has been
shown to positionally alter the VP55 RNA contact site
[62].
W e observed an R342H substitution (T able 1) within
the VP55 C domain dimerization region interface of
VP39 and VP55 (Figure 11A, B) [63]. Predictive modeling
suggests that the R342H substitution decreases regional
surface exposure (C domain residues 337-344) and
induced a flexible coil region at the 342 locus (data not
shown). Such alterations in the secondary structure
within this region could alter both the VP55-VP39 inter-
action interface (yellow dashed line - Figure 11B) as well
as the upstream proximal linker segment that supports
the catalytic domain of VP55 [63]. Previously, nucleotide
analogs have been postulated to negatively affect poly-
adenylation and early mRNA extrusion from the viral
core [64]. In addition, nucleotide content within VP55
oligonucleotide primer recognition motifs may affect the
timing of gene expression [64]. As a cytosine analog,
CDV, if incorporated into priming sequences, could alter
the primer reaction site and impart some selection pres-
sure to maintaining effective VP55-primer recognition
and subsequent processive polyadenylation of mRNA
transcripts.
Conclusion
In the current study we report the complete genomic
sequence of a CDV-R strain of MPV. In addition, we pres-
ent a focused and comparative bioinformatic analysis that
revealed predicted alterations in topological features of
functionally active domains within essential virus pro-
teins. Previous data indicate mutations at sites 314 and
684 in the DNApol represent the primary determinants
of CDV-R in VACV [15,20]. Although second-site substi-
tutions elsewhere in the VACV genome have been impli-
Figure 7 MPV CDV-R c-terminal amino acid deletion mapped on 
3-D structure of VACV thymidylate kinase (TMPK) homodimer. 
The four residues corresponding to the c-terminal frameshift mutation 
in MPV CDV-R are labeled in blue and pink. Illustrations were prepared 
using Cn3D. Inset includes space-filling model of the four c-terminal 
residues of WT and CDV-R MPV TMPK (prepared using Lasergene soft-
ware).Farlow et al. Virology Journal 2010, 7:110
http://www.virologyj.com/content/7/1/110
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cated previously in a CDV-R clone [18], they have yet to
be identified. The present study may provide clues to the
location of such mutations. The MPV DNApol mutations
reported here provide the first indication that CDV-R loci
previously identified in VACV are perhaps conserved in
fully-virulent, non vaccine strains, though such specula-
tion must await experimental validation. Such data may
inform efforts in development of Smallpox-related medi-
cal countermeasures. Any direct effects of selected muta-
tions reported here on the resistant or attenuated
phenotype of MPV must await future determination.
These regions may be of particular interest for future site-
Figure 8 MPV CDV-R substitutions mapped onto the 3-D structure of S. cerevisiae RNA pol II (GenBank # CAA65619.1). The MPV CDV-R L653R 
residue mapped to the yeast RNA pol II funnel domain is designated in yellow (A-C). The MPV CDV-R K355N residue mapped to the docking domain 
of yeast RNA pol II is designated in orange. Yeast residues Leu737 (blue) and Phe755 (magenta) are associated with α-amanitin resistance [46]. Illus-
trations were prepared using PyMol.Farlow et al. Virology Journal 2010, 7:110
http://www.virologyj.com/content/7/1/110
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directed mutagenesis studies to dissect 1) potential yet-
uncharacterized mutations elsewhere in the genome that
may play a role in the CDV-R phenotype, and, 2) the
genetic basis of the characteristic attenuated phenotype
of CDV-R poxviruses. It is possible the substitutions
observed in our analysis outside the viral DNA poly-
merase, for example in the RNA polymerase and mRNA
capping enzyme, may contribute to the resistant or atten-
uated phenotype of CDV-R MPV. Such changes may rep-
resent compensatory, adaptive, or attenuating variations
in gene expression or replication. Also, adaptive substitu-
tions which support a CDV-R phenotype may result in
alterations in the timing of the viral gene expression pro-
gram that could reduce fitness compared to wild-type yet
sustain gene expression in the presence of CDV. Both
adaptive and non-adaptive substitutions may also be
facilitated through mutator alleles in the DNA or RNA
polymerases. As DNA synthesis is a key regulator of gene
expression in poxviruses, it is possible the aberrant chain
extension induced by CDV may lead to diverse alterations
in gene expression and replication that must be overcome
by a resistant strain. The genome sequence of CDV-R
MPV may inform future research into the mechanism of
action of CDV as well as dissection of the phenotypic
Figure 9 MPV CDV-R RNA pol substitutions mapped onto the 3-D structure of S. cerevisiae RNA pol II. CDV_R substitution K355N (orange) and 
L653R (yellow) mapped to the 3-D structure of A) binding sites of TFIIB (purple) on yeast RNA pol II and B) TFIIS (teal) [70], respectively. Illustrations 
were prepared using PyMol.
Figure 10 MPV CDV-R mutations mapped onto the 3D structures of the poxvirus D1/D12 mRNA capping enzyme. S186 which lies within the 
conserved motif 183-KCVSDSWLKDS (F, red residues) plays a major role in proper tertiary folding [54]. Yellow residues (E and F) designate the D12 
hetero-dimerization motif [54]. D1 residues T84 (magenta) and S589 (teal) specify residues in closest proximity to the D12 S186N substitution (E). Illus-
trations were prepared using PyMol.Farlow et al. Virology Journal 2010, 7:110
http://www.virologyj.com/content/7/1/110
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properties of resistant poxviruses. Furthermore, defining
the potential contribution of substitutions in the replica-
tion complex and RNA processing machinery may inform
current therapeutic development strategies and yield fur-
ther insight into CDV-resistance and attenuation.
Methods
Viral DNA extraction, amplification and sequencing
The CDV-R strain of MPV Zaire-005 sequenced in this
study was previously characterized by Smee et al 2002
(15). Poxvirus DNA were extracted from virus-infected
cells utilizing the Aquapure DNA kit (Bio-Rad, Hercules,
CA). Prior experiments demonstrated that the material
was noninfectious after 60 min of incubation at 55°C in
the Aquapure lysis buffer. The PCR amplification and
sequencing primers were designed to cover the entire
genome in overlapping fragments of about 500-600 bases.
Primers were designed by the aid of PrimerSelect V 7.0.0
(DNASTAR, Madison, WI) using general guidelines for
primers design. The criteria were as follows: Tm: 48°C to
63°C (optimum 55°C); GC content: 30-80% (optimum
50%); 3' GC clamp: none; size: 18 to 27 (optimum 20);
secondary structure: 0 to 8 with a maximum of 3 bp self-
complementarities at the 3' end. The melting temperature
was determined according to Breslauer et al [65].
PCR was performed in 25-μl volume containing a PCR
buffer (20 mM Tris-HCl, pH 8.4, 50 mM KCl), 3 mM
MgCl2, 0.2 mM dNTP mix, 0.4 uM of each primer for-
ward and reverse, 2 U of Platinum Taq DNA polymerase
(Invitrogen Life Technologies, Carlsbad, CA), and 3 pg of
DNA template. The amplification reaction was carried
using the cycler PTC100 (MJ Research, Reno, NV) with
the following cycling conditions: 94°C for 2 min, 45 cycles
of 94°C for 30 sec, 50°C for 15 sec, and 72°C for 1 min,
and one cycle of 72°C for 5 min. The PCR product was
stored at 4°C until use.
Genome sequences were determined by capillary
sequencing using the ABI Prism BigDye Terminator
Cycle Sequencing Kit 3.1 (Applied Biosystems, Foster
City, CA) and the manufacturer's instructions for PCR
product sequencing. Cycle sequencing reactions were
carried out on MJ Research PTC100 thermal cycler (MJ
Research, Reno, NV). Labeled products were analyzed in
an ABI 3700 Genetic Analyzer (Applied Biosystems). The
resultant sequence reads were assembled into contigs
using Lasergene 7 software, (DNASTAR). Consensus
DNA sequences were obtained at least 3-fold redundancy
at each base locus. The CDV-R MPV genome sequence
has been deposited in GenBank under accession No.
HM172544.
Genome comparison
The MEGA 4.0 software package [66] was used for SNP/
indel identification and whole genome sequence compar-
isons of CDV-R and WT Zaire 79-005. The genome of
the seed stock used in the analysis (WT Zaire 79-005)
was sequenced and compared with the genome of the
final CDV-R passage.
Protein sequence and predictive structural analysis
MEGA 4.0 was used to generate amino acid alignments.
Topological feature maps containing predictive protein
secondary structure analysis output was carried out using
the Protean module of Lazergene (DNAstar) software
under default settings. Motif surface exposure at MVP
Figure 11 MPV CDV-R mutations mapped onto the 3D structures of poxvirus poly-A polymerase VP55. The R342H mutation (yellow) is pre-
sented in the ribbon diagram topology (A) and space filling model (B). Dashed yellow line (B) designates the VP55-VP39 interface.Farlow et al. Virology Journal 2010, 7:110
http://www.virologyj.com/content/7/1/110
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CDV-R substitution loci were estimated using the Jame-
son-Wolf antigenic index and the Emini method. The
antigen index integrates hydropathy, conventional solvent
accessibility, and flexibility to produce a linear surface
contour plot [67] and provides a more comprehensive
surface exposure estimate than the Emini method [68],
which evaluates side-chain solvent accessibility alone (i.e.,
Emini plot). 3-D protein structures were modeled using
PyMol software [69] and Cn3D software http://
www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml.
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